is an emerging pathogen that causes pulmonary mucormycosis.
We report a case of pneumonia caused by
in a 54-year-old type 2 diabetic patient. The organism was isolated from bronchoalveolar lavage ...fluid and preliminarily identified by fungal morphology and finally by sequencing of the internal transcribed spacer region.
Mucormycosis may be associated with cavitary lung lesions against a backdrop of poorly controlled diabetes or other immunosuppressed states. Pulmonary mucormycosis may have variable clinical and radiological presentations. Therefore, strong clinical suspicion and prompt management can address the high fatality associated with the disease.
At JADPRO Live 2022, Jonathan Treem, MD, of the University of Colorado Palliative Care, explained medical aid in dying in order to prepare advanced practitioners to feel confident to counsel a ...patient who inquiries about aid in dying. He explained the law and protocol for participation, the history, ethics, and data behind the intervention, and steps for what is required. Finally, Dr. Treem discussed ethical considerations that may arise as patients and clinicians consider these types of interventions.
In the popular biomarker-focused session at JADPRO Live 2022, presenters paired biomarkers with tumor types for which their expression is most commonly used to determine targeted therapy, identified ...key assays used to measure common biomarkers, and reviewed recommendations and guidelines for biomarker testing.
Therapeutic options for patients with multiple myeloma have multiplied in the past decade. However, multiple myeloma remains an incurable disease, and relapsed/refractory myeloma is characterized by ...genetic and cytogenetic alterations that drive resistance and result in progressively shorter durations of remission to each subsequent therapy. At JADPRO Live 2022, presenters discussed the multifactorial process for choosing the right therapy for a particular patient and strategies to manage unique treatment complications associated with novel treatment modalities used for patients with relapsed/refractory multiple myeloma.
HER2 is overexpressed and/or amplified in approximately 20% of breast cancers. It is a clinically aggressive subtype; however, the introduction of targeted therapies has greatly improved survival ...rates. At JADPRO Live 2022, presenters discussed recent updates to clinical practice for HER2-positive metastatic breast cancer, and how to interpret emerging evidence on HER2-low data. They also highlighted best practices for monitoring and managing side effects for patients on these therapies.
Multiple primaries are defined as more than one synchronous or metachronous cancer in the same individual. They can pose challenges to clinicians, as the goal is to find an anticancer therapy ...strategy that covers both cancer types without increased toxicity or drug interactions, and does not negatively impact a patient's overall outcome. At JADPRO Live 2022, presenters tackled this complicated topic by reviewing diagnostic criteria, epidemiology, and risk factors, demonstrating the prioritization of treatment, and discussing the role of the advanced practitioner in collaborative, interdisciplinary management of the patient with multiple primary tumors.
The risk of developing venous thromboembolism (VTE) is four to seven times higher in patients with cancer than in those without. At JADPRO Live 2022, presenters discussed risk factors and assessing ...patients for VTE, as well as how to protect patients against VTE in both the inpatient and outpatient clinic settings. They reviewed selecting an appropriate anticoagulation treatment, including the choice of agent and duration of treatment for the patient with cancer, and finally the steps needed to assess and treat patients experiencing therapeutic anticoagulation failure.
PDF
